CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Net product sales	$ 2,689,478	$ 1,750,762	$ 1,425,839
Sanofi collaboration revenue	758,873	541,299	430,111
Bayer HealthCare collaboration revenue	580,488	495,555	220,289
Other revenue	74,889	31,941	28,506
Total revenues	4,103,728	2,819,557	2,104,745
Expenses:
Research and development	1,620,577	1,271,353	859,947
Selling, general, and administrative	838,526	519,267	346,393
Cost of goods sold	241,702	129,030	118,048
Cost of collaboration and contract manufacturing	151,007	75,988	37,307
Total expenses	2,851,812	1,995,638	1,361,695
Income from operations	1,251,916	823,919	743,050
Other income (expense):
Investment and other income (expense)	6,283	8,157	(231)
Interest expense	(14,241)	(37,372)	(46,437)
Loss on Extinguishment of Debt	(18,861)	(33,469)	0
Total other income (expense)	(26,819)	(62,684)	(46,668)
Income before income taxes	1,225,097	761,235	696,382
Income tax expense	(589,041)	(423,109)	(282,644)
Net income	$ 636,056	$ 338,126	$ 413,738
Net income per share - basic	$ 6.17	$ 3.36	$ 4.23
Net income per share - diluted	$ 5.52	$ 2.98	$ 3.72
Weighted average shares outstanding - basic	103,061	100,612	97,917
Weighted average shares outstanding - diluted	115,230	113,413	111,290
Statements of Comprehensive Income
Net income	$ 636,056	$ 338,126	$ 413,738
Other comprehensive income:
Unrealized gain (loss) on marketable securities, net of tax	(43,679)	53,439	(22)
Comprehensive income	$ 592,377	$ 391,565	$ 413,716